Figma's CEO says AI is empowering 'generalist behavior'
"This was happening before AI, but it's happening even more with AI," Figma's CEO Dylan Field said at a talk with Y Combinator published on Saturday. "There's something about AI that empowers generalist behavior."
Field said that areas that were seen as distinct phases in the product development process are now merging.
"Product is also blurring with design and development and potentially even parts of research," he said. "All this is becoming less distinct, and it's all kind of coming together more."
In what was seen as the hottest listing of the year, Figma went public on July 31 at a $19.3 billion valuation, three years after Adobe was set to acquire the design software startup for almost the same amount. By market close that day, Figma's stock had more than tripled its initial public offering price, valuing the company at nearly $68 billion, giving its Silicon Valley investors a big payday. It brought to an end a three-year tech IPO dry spell, and the company threw a massive block party in front of the New York Stock Exchange.
The company's valuation has since slid to $38 billion.
At the YC talk, Field also said designers would become more important with AI.
"In this age of AI, if you really believe that development gets easier and it's more simple to create software, it's faster to create software. Then what is your differentiator?" he said. "It's design, it's craft, it's attention to detail."
Field added that designers will have more leverage in the future and more will step into founder and leadership roles.
"There will be a lot of curation involved and a lot of leadership will be needed from designers," he said. "So they have to step up."
Figma did not immediately respond to a request for comment from Business Insider.
Field is far from the first tech leader to extoll the value of generalists. Silicon Valley leaders have been recommending that more people become generalists instead of specialists as AI changes the nature and need for certain careers.
Earlier this month, the billionaire venture capitalist Vinod Khosla said he suggests young people don't plan their career around any one job.
"You have to optimize your career for flexibility, not a single profession," he said on a podcast. "That's the most important advice because you don't know what will be around."
Andreessen Horowitz founder Marc Andreessen said he advised people outside domains like biotech and AI Foundation models to go broader instead of deeper.
"I think for most fields, though, now with these new tools, I would probably bet more on basically people who are able to be broad," he said on a May podcast.
"Which is to say basically knowing something about a lot of different aspects of life and how the world works."
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 minutes ago
- Yahoo
Rumble announces intention to buy Northern Data
Rumble, a provider of video-sharing platform and cloud services, has announced its intention to acquire Northern Data, a provider of AI and high performance computing (HPC) solutions. The development follows a simultaneous announcement from Northern Data, indicating that Rumble has expressed interest in pursuing a potential exchange offer. Under the proposed terms, shareholders of Northern Data would receive newly issued Class A shares of Rumble common stock in exchange for their Northern Data shares tendered in the potential offer. Northern Data has indicated a willingness to engage in further discussions regarding this proposal. Should the transaction proceed, the merged entity aims to focus on leadership in AI while prioritising data privacy and independence on a global scale, stated Rumble. The key aspects of the potential offer suggest that each Northern Data shareholder who tenders their shares would receive 2.319 newly issued Class A Rumble shares for each Northern Data share. If all outstanding shares of Northern Data are tendered, this would result in approximately 33.3% pro forma ownership in Rumble for Northern Data shareholders. The final exchange ratio will be established after confirmatory due diligence and negotiations, and it may be adjusted based on the potential sale of Northern Data's Peak Mining unit, which could influence the exchange ratio and other balance sheet considerations. Post-transaction, Tether is projected to become the largest holder of Rumble's Class A common stock, while Chris Pavlovski, Rumble's chairman and CEO, is expected to maintain a majority of the voting power. Pavlovski has expressed his support for the potential offer and intends to vote in favour of the transaction. Rumble's proposal assumes that Northern Data's Peak Mining unit will be sold before the completion of the offer, with the proceeds aimed at reducing an existing loan from Tether to Northern Data. The remaining loan is expected to continue as an obligation of Northern Data, with Rumble seeking to structure it to avoid any liability for Rumble and its subsidiaries. If the potential offer is realised, Rumble anticipates a significant transformation into a global leader in AI cloud services. Northern Data's assets include a substantial number of Nvidia GPUs and multiple data centre sites with considerable capacity. Tether, a player in the digital assets sector and the leading dollar stablecoin, has expressed its support for the potential acquisition. In connection with the potential offer, Tether has indicated its intention to sell its entire stake in Northern Data, which represents around 54% of the company's outstanding shares, to Rumble in exchange for newly issued Class A shares. This move would significantly increase Tether's investment in Rumble. Additionally, Tether plans to become a key customer of Rumble post-transaction, committing to a multi-year GPU purchase agreement and amending the existing loan to Northern Data to provide financial flexibility for the acquired business. Guggenheim Securities is serving as the financial advisor, while Willkie Farr & Gallagher LLP is providing legal counsel to Rumble. "Rumble announces intention to buy Northern Data" was originally created and published by Verdict, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.
Yahoo
2 minutes ago
- Yahoo
Asia-Pacific Molecular Oncology Diagnostics Market Research 2024-2033
The Asia-Pacific molecular oncology diagnostics market, valued at $513.6 million in 2024, is projected to surge to $1.54 billion by 2033 with a CAGR of 12.99%. Key technologies like digital PCR, liquid biopsy, and next-generation sequencing are driving growth amid rising cancer rates in China, India, and Japan. While high costs and a shortage of skilled professionals challenge expansion, collaborations and innovations are enhancing molecular diagnostic adoption. Strategic efforts, including AI, reimbursement standardization, and genomic literacy programs, aim to advance precision oncology in the APAC region, addressing barriers and harnessing growth opportunities. Asia-Pacific Molecular Oncology Diagnostics Market Dublin, Aug. 11, 2025 (GLOBE NEWSWIRE) -- The "Asia-Pacific Molecular Oncology Diagnostics Market: Focus on Cancer Type, End User, and Country - Analysis and Forecast, 2024-2033" has been added to Asia-Pacific molecular oncology diagnostics market was valued at $513.6 million in 2024, and the market is expected to grow with a CAGR of 12.99% and reach $1.54 billion by 2033. Digital PCR, liquid biopsy, and next-generation sequencing (NGS) are the main technological factors propelling the APAC molecular cancer diagnostics market's explosive expansion. The need for earlier detection, more accurate therapy choices, and ultimately improved patient outcomes is being fuelled by the rising incidence of cancer in nations like China, India, and Japan. The market for molecular oncology diagnostics in Asia-Pacific (APAC) is expected to grow quickly as healthcare systems in China, India, Japan, and Southeast Asia place a greater emphasis on precision medicine. The use of molecular assays, especially next-generation sequencing (NGS), digital PCR, and liquid biopsy, is growing because they can more precisely and early identify genetic changes linked to cancer than conventional techniques. The demand for these cutting-edge instruments is being driven by the rising prevalence of colorectal, lung, and breast cancers as well as increased patient and physician awareness. Clinical adoption is also being accelerated by national genomics programs, companion diagnostics recommendations, and public and private investments in laboratory infrastructure. High test prices, disjointed regulatory procedures, and a lack of qualified bioinformaticians and molecular technologists, particularly in lower-income regions, continue to be major participants are establishing strategic alliances, increasing locally produced goods, and putting in place training initiatives to develop technological know-how in order to overcome these obstacles. Automated high-throughput platforms are being implemented in the meanwhile to expedite processes and shorten turnaround times. In the future, the combination of AI-powered bioinformatics, increased reimbursement coverage, and more robust data-security frameworks will be essential for promoting long-term industry expansion. By providing more individualised, efficient cancer treatment in a variety of healthcare settings, the APAC molecular oncology diagnostics market is anticipated to take a sizable chunk of the worldwide precision oncology market by 2030. Key Attributes: Report Attribute Details No. of Pages 80 Forecast Period 2024 - 2033 Estimated Market Value (USD) in 2024 $513.6 Million Forecasted Market Value (USD) by 2033 $1542 Million Compound Annual Growth Rate 12.9% Regions Covered Asia Pacific APAC Molecular Oncology Diagnostics Market Trends, Drivers & Challenges: Market Trends Technological Advancements: Rapid uptake of next generation sequencing (NGS), digital PCR and liquid biopsies (ctDNA/ctC) for non invasive, real time cancer monitoring. Consolidation & Partnerships: Increased M&A activity reshaping the competitive landscape, with major lab and diagnostics players acquiring or partnering on advanced platforms. Companion Diagnostics Integration: Growing adoption of CDx assays to match patients with targeted therapies, supported by evolving regulatory guidelines in key markets like Japan and Australia. Automation & High Throughput Platforms: Deployment of automated systems in both clinical and research labs to boost efficiency and sample throughput. Market Drivers Rising Cancer Incidence: Surging rates of breast, lung and colorectal cancers across China, India, Japan and Southeast Asia fueling demand for precise diagnostics. Precision Medicine Push: Strategic shift toward personalized oncology, with payers and providers investing in genotype-guided treatment pathways. Government & Public-Private Initiatives: National programs and partnerships underwriting infrastructure expansion, including genomics missions and companion diagnostics guidelines. Healthcare Infrastructure Investments: Capital inflows into lab upgrades, biotech R&D and specialized cancer centers enhancing regional capacity. Market Challenges High Cost of Testing: Advanced molecular assays remain expensive, limiting penetration in lower income APAC markets. Regulatory Complexity: Fragmented and evolving approval pathways across different countries delay product launches. Skilled Workforce Shortage: Insufficient numbers of trained molecular technologists and bioinformaticians impede broader clinical rollout. Data Security & Privacy: Handling of sensitive genomic and patient data raises compliance and cybersecurity concerns. Market Segmentation: Cancer Type Solid Tumors Hematologic Malignancies End User Hospitals and Diagnostic Centers Reference Laboratories Pharmaceutical and Biotechnology Companies Academic and Research Institutes Region Japan, China, India, South Korea, Australia, and Rest-of-Asia-Pacific For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachment Asia-Pacific Molecular Oncology Diagnostics Market CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900
Tom's Guide
4 minutes ago
- Tom's Guide
GPT-5 users aren't happy with the update — try these alternative chatbots instead
For months, the OpenAI team has been building up to a massive launch. They spoke of a landscape-changing update that would change what AI could do. Now, that update is here in the form of GPT-5. However, not everyone is happy with this newest version of ChatGPT. Critics have complained that not only is it not a great update, but that they would rather use the earlier version over this. However, once your device updates to GPT-5, there is no option to use older versions of the tool. OpenAI has since said that it will correct this, offering users the ability to use GPT-4 instead. Of course, this is still the early days. GPT-5 will get better over time with updates as the team has had the chance to understand how people are using it. Not everyone is unhappy either, there seems to be a big split, with just as many enjoying the tool as those who aren't getting on with it. However, if you fall into the camp that feels let down by GPT-5, the good news is that this is a packed market. There are plenty of other great tools on the market to try instead. These are our top picks. Google and OpenAI have been battling it out since the earliest stages of chatbots. The two titans of tech have the money and technology to be the best, and that makes Gemini a worthy opponent for ChatGPT. With Gemini, you're getting one of the best chatbots for coding, and also a model that isn't quite as sycophantic as ChatGPT. Get instant access to breaking news, the hottest reviews, great deals and helpful tips. Gemini has a lot of the same features as ChatGPT, and also offers fairly similar benefits in the tool. One feature that stands out with Gemini is the depth of its deep research. It can produce incredibly detailed responses, diving into every corner of the internet for your isn't as stylish as ChatGPT, and it does have a tendency to misunderstand what you're asking sometimes, and we've noticed a higher rate of hallucinations. However, it is an otherwise great ChatGPT alternative. Claude has very quickly risen through the ranks to become a leading competitor in this crowded market. The chatbot has a focus on deliberate and careful research, and the team behind the tool reflects this. They perform lots of independent research and have created a chatbot that feels in keeping with that philosophy. It's great for coding, allowing you to publish any tool you code onto its own web link, and offers a wide variety of pre-built apps to explore. Like Gemini, it is also more to-the-point than ChatGPT, focusing less on being friendly and more on getting you an immediate answer. While it has always performed well on benchmarks, it hasn't been as successful as ChatGPT or Gemini overall, but over the next few years, it will be a truly competitive force of nature. One feature, that will either make or break it for you, is that Claude has no memory. That means, unlike ChatGPT and Gemini, it can't store information about you. ChatGPT uses this information to personalize answers, giving responses that better fit your needs. xAI's Grok has a slippery reputation. On benchmarks, it is one of the most powerful AI chatbots around. It is great for coding and has proved to be a formidable force when it comes to deep research. However, it has also found itself in constant controversy, whether thats because of its AI girlfriend feature, or repeated mistakes where the chatbot accidentally starts to support conspiracy theories. Grok doesn't get the same recognition as the options above, and there is good reason for that, with a somewhat mixed bag of experiences. However, that is not to say it isn't one of the best chatbots on the market, especially when put through legitimate AI tests. Perplexity isn't technically a chatbot. Think of it more like an overpowered Google, complete with lots of AI tricks up its imaginary sleeve. If you've been using ChatGPT as an alternative to Google, Perplexity could feel like a natural fit. It thrives when you ask it questions, or if you're simply using ChatGPT to learn new information about the world around you. However, it falls down in some of the newer features we're seeing in chatbots. Its image and video generation isn't as good as the competitors', and it can't generate code like its alternatives. While it is more than capable of handling most queries, it does have some areas that fall outside of its remit. However, these are few and far between for the average user. One of the lesser-known options out there right now, Le Chat is a French chatbot service created by Mistral. It doesn't perform as well as its peers above on benchmarking, and arguably isn't quite as smart. However, it makes up for that in other ways that might be important to certain users. In a recent examination, it scored the highest out of all chatbots on its privacy and how it deals with data, it also has a function for ultra-fast responses, where it will generate 10 times faster than normal. On top of that, Le Chat doesn't store any data from your conversations and, like Claude, it doesn't have a memory of previous chats. In other words, this is the model to switch to for the privacy concerned.
